Polymeric nanoparticles
Polymeric nanoparticles are at the forefront of advanced drug delivery, revolutionizing nanomedicine through their high tunability and precise control over particle properties.
The most tunable nanoparticle platform in drug delivery. We know how to use it.
We have experience with polymeric nanoparticles that spans polymer synthesis, self-assembly, surface functionalisation, and analytical characterisation. Polymeric systems offer something lipid and inorganic nanoparticles cannot always match — exceptional tunability. Particle size, shape, surface properties, and drug release profiles can all be independently engineered to match your therapeutic requirements. For programmes targeting controlled release, cell-specific delivery, or encapsulation of challenging payloads including small molecules, nucleic acids, and proteins, polymeric nanoparticles offer a highly flexible and scientifically compelling platform.
01
Why Polymeric Nanoparticles
Why use polymeric nanoparticles?
Polymeric nanoparticles serve as drug delivery carriers for active pharmaceutical ingredients (APIs). They typically range up to several hundred nanometers in diameter and are engineered from (biocompatible) polymers.
Their small size facilitates efficient cellular uptake, while the broad scope of polymers allows for tailored properties to ensure optimal drug release profiles and target specificity. Polymeric nanoparticles also offer versatility and can accommodate a wide range of therapeutic payloads, including small molecules, nucleic acids and proteins.
02
Process Development
Experts in polymeric nanoparticle development
Our team of polymer experts crafts your polymeric nanoparticles. With years of experience in the synthesis and self-assembly of polymers, we can bring your product from a small-scale procedure to pilot-scale production.
We have experience in polymeric nanoparticle developments using a variety of polymers, such as block copolymers, cross-linked polymers and dendrimers.
03
Analytical Development
Our analytical capabilities
Our team of analytical experts has extensive experience with various polymeric nanoparticles, including those from synthetic copolymers (e.g., PEG, PLA) or biopolymers (e.g., carbohydrates, proteins, polypeptides). Utilizing chromatographic and spectroscopic techniques, we quantify and determine (bio)polymer molecular weight distribution and various types of APIs, such as small-molecule drugs, peptides and oligonucleotides.
Additionally, we can determine critical characteristics of polymeric nanoparticles, such as particle size distribution, morphology (e.g., spherical or rod-like structures, micelles), surface charge and in-vitro release. Our analytical solutions offer comprehensive insights to support the development of polymeric nanoparticle formulations for various applications.
- Appearance: Visual
- Identity: FT-IR, NMR
- Identification and quantification of (encapsulated) API and related impurities:
- Small-molecule drugs: LC-UV/CAD/MS
- Peptide/proteins: LC-UV/MS, AAA
- Oligonucleotides and mRNA: IPLC-UV/MS, qPCR, CGE (Fragment Analyzer), RiboGreen
- Quantification of polymers: LC-UV/CAD, GPC, qNMR
- Molecular weight distribution of polymers: GPC, AF4/SEC-MALS
- Particle size distribution: DLS, AF4/SEC-MALS, TEM
- Morphology: AF4/SEC-MALS, TEM
- Surface properties: ELS (zeta potential)
- Elemental impurities: ICP-MS
- Residual solvents: GC-HS, GC-FID/MS
- Solution properties (pH, osmolality), in vitro release, microbiological control: USP/Ph. Eur.
At Ardena, we stay at the forefront of technological advancements, continuously innovating to provide state-of-the-art solutions tailored to your unique project requirements. We value collaboration and work closely with clients to understand their needs and deliver the desired polymeric nanoparticle solutions.
04
Our Experience
Our experience and success stories
Our commitment to excellence is evident in our successful track record with polymeric nanoparticles. Ardena has played a pivotal role in advancing numerous projects, including:
A Innovative polymerization systems
Free radical polymerization systems, including custom monomer and initiator synthesis, for generating block copolymer architectures for drug encapsulation and delivery applications.
B Advanced covalent functionalization methods
Covalent functionalization approaches for dendritic nanoparticle-API conjugates through the application of click chemistry and the subsequent purification and formulation of the nanoparticle product.
Related resources
Our expert team members share their deep, scientific understanding and insights into nanomedicine development and manufacturing.
-
Info sheets
Secondary Packaging Built for Complex Clinical Trials
Read more -
Info sheets
Flow Cytometry with Ardena: Bespoke, Backbone and Built
Read more -
Case studies
Enabling Complex Phase IIa Dosing Through Flexible Clinical Packaging Design
Read more -
Whitepapers
Advancing Pharmaceutical Production: The Benefits of Flow Manufacturing for Nanomedicines
Read more -
Info sheets
ADC & XDC Development, from Chemistry to Clinic
Read more -
Application Note
Informatics-Supported Solid Form Selection
Read more -
Case studies
Achieving High Drug Tolerance in ADA Testing for a Long-Acting Monoclonal Antibody
Read more -
Webinars
On-Demand Webinar: Nanomedicine Development from Lab to Clinic: Strategies to Overcome Scale-Up and Analytical Challenges
Read more -
Whitepapers
Evolution of Stability Guidelines: From the ICH Q1A-F Series to the Consolidated ICH Q1 Guideline
Read more
